{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:11:37Z","timestamp":1778901097916,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vasdi.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:48:31Z","timestamp":1772228911000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5914-8905","authenticated-orcid":false,"given":"Abdul Mueez Alam","family":"Kayani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Faiq","family":"Umar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Navarro-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Affan","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricky E.","family":"Lemus-Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vasdi.2026.02.004_bib0225","series-title":"Cardiovascular diseases (CVDs) [Internet]","year":"2025"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0230","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0235","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0240","doi-asserted-by":"crossref","first-page":"100010","DOI":"10.1016\/j.ajpc.2020.100010","article-title":"Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States","volume":"1","author":"Klimchak","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0245","first-page":"860","article-title":"Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease","volume":"19","author":"Worledge","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0250","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22713","article-title":"PCSK9 inhibitor access barriers \u2014 issues and recommendations: improving the access process for patients, clinicians and payers","volume":"40","author":"Baum","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0255","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy \u2014 European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0260","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0265","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0270","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0275","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0280","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0285","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0290","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0295","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0300","series-title":"A Study of Obicetrapib in Participants With Heterozygous Familial Hypercholesterolemia (BROOKLYN) [Internet]","author":"ClinicalTrials","year":"2022"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0305","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on major adverse cardiovascular events in high-risk patients: a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0310","doi-asserted-by":"crossref","first-page":"101303","DOI":"10.1016\/j.ajpc.2025.101303","article-title":"Efficacy and safety of obicetrapib in patients with dyslipidemia: an updated meta-analysis of randomized controlled trials","volume":"24","author":"Ara\u00fajo","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0315","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0320","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0325","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0335","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","article-title":"Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis [last updated August 2024]","author":"Page","year":"2024"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0340","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0345","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","article-title":"Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0350","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0355","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0360","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","article-title":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease","volume":"43","author":"Sammons","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0365","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/eurheartj\/ehab889","article-title":"CETP inhibitors revisited","volume":"43","author":"Laufs","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0370","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2024.12.016","article-title":"Lipid-lowering efficacy of obicetrapib: a comprehensive systematic review and meta-analysis","volume":"19","author":"Masson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0375","doi-asserted-by":"crossref","first-page":"e064541","DOI":"10.1136\/bmjopen-2022-064541","volume":"13","author":"Morgan","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0380","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0385","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0395","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1161\/ATVBAHA.112.300133","article-title":"High-density lipoprotein function, dysfunction, and reverse cholesterol transport","volume":"32","author":"Fisher","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0400","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s11886-023-01987-3","article-title":"High-density lipoprotein cholesterol in atherosclerotic cardiovascular disease risk assessment: exploring and explaining the \u201cU\u201d-shaped curve","volume":"25","author":"Razavi","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0405","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.ihj.2023.12.001","article-title":"Apolipoprotein B \u2014 an ideal biomarker for atherosclerosis?","volume":"76","author":"Singh","year":"2024","journal-title":"Indian Heart J"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0410","doi-asserted-by":"crossref","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0415","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12872-024-03949-1","article-title":"Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0420","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0425","doi-asserted-by":"crossref","first-page":"103845","DOI":"10.1016\/j.numecd.2024.103845","article-title":"LP(a): the new marker of high cardiovascular risk","volume":"35","author":"Averna","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0430","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0435","year":"2022"},{"key":"10.1016\/j.vasdi.2026.02.004_bib0440","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ahj.2025.07.012","article-title":"Rationale and design of the REMBRANDT trial: a phase 3 study to evaluate the effect of obicetrapib\/ezetimibe on coronary plaque characteristics","volume":"290","author":"McCarthy","year":"2025","journal-title":"Am Heart J"}],"container-title":["Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658126001767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658126001767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:25:43Z","timestamp":1778898343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050658126001767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050658126001767"],"URL":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.02.004","relation":{},"ISSN":["3050-6581"],"issn-type":[{"value":"3050-6581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}